We have data on 1,054 companies that use Cepheid GeneXpert. The companies using Cepheid GeneXpert are most often found in United States and in the Hospital & Health Care industry. Cepheid GeneXpert is most often used by companies with 1000-5000 employees and 200M-1000M dollars in revenue. Our data for Cepheid GeneXpert usage goes back as far as 6 years and 9 months.
Company | Rutgers University-Camden |
Website | rutgers.edu |
Country | United States |
Revenue | 100M-200M |
Company Size | >10000 |
Company | Duke University |
Website | duke.edu |
Country | United States |
Revenue | >1000M |
Company Size | >10000 |
Company | Website | Country | Revenue | Company Size |
---|---|---|---|---|
Rutgers University-Camden | rutgers.edu | United States | 100M-200M | >10000 |
Duke University | duke.edu | United States | >1000M | >10000 |
We use the best indexing techniques combined with advanced data science to monitor the market share of over 15,000 technology products, including Healthcare. By scanning billions of public documents, we are able to collect deep insights on every company, with over 100 data fields per company at an average. In the Healthcare category, Cepheid GeneXpert has a market share of about 0.6%. Other major and competing products in this category include:
Cepheid's GeneXpert is a fully integrated and automated on-demand molecular diagnostic system. The GeneXpert System is available in a one, two, four, 16, 48, or 80-module configuration. All have Cepheid's proven GeneXpert module at their analytic heart, and use the same patented cartridge technology for every Xpert test.
Looking at Cepheid GeneXpert customers by industry, we find that Hospital & Health Care (60%) and Higher Education (6%) are the largest segments.
64% of Cepheid GeneXpert customers are in United States and 6% are in United Kingdom.
Of all the customers that are using Cepheid GeneXpert, a majority (64%) are large (>1000 employees), 7% are small (<50 employees) and 28% are medium-sized.
Of all the customers that are using Cepheid GeneXpert, 37% are small (<$50M), 10% are medium-sized and 44% are large (>$1000M).